Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 75/100

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

Key Takeaway: Insmed Incorporated (Nasdaq: INSM) will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation is part of Insmed's efforts to highlight their advancements in therapies for serious diseases. The event will be available for live streaming, indicating the company's commitment to transparency with investors. Insmed is noted for its diverse and innovative portfolio of therapies, as well as its recognition as a top employer in the industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is recognized as a top employer in the biopharmaceutical industry.
  • The company is advancing a diverse portfolio of innovative therapies.
  • Management's presentation at a premier healthcare conference highlights company visibility.

Full Press Release Details

BRIDGEWATER, N.J. , Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025 , at 3:00 p.m. PT / 6:00 p.m. ET .
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . Webcasts will be archived for a period of 30 days following the conclusion of the live events.
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey , Insmed has offices and research locations throughout the United States , Europe , and Japan . Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.
Bryan Dunn Executive Director, Investor Relations (646) 812-4030 [email protected]
Michael V. Morabito , Ph.D. Director, Investor Relations (917) 936-8430 [email protected]
Gianna De Palma Manager, Investor Relations (973) 886-2236 [email protected]
Mandy Fahey Vice President, Corporate Communications (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

When will Insmed present at the J.P. Morgan Healthcare Conference?

Insmed will present on January 13, 2025, at 3:00 p.m. PT.

How can I access the live webcast of Insmed's presentation?

The live webcast can be accessed via Insmed's investor relations section online.

What types of therapies is Insmed focused on developing?

Insmed develops best-in-class therapies for pulmonary and inflammatory conditions.

Where is Insmed Incorporated headquartered?

Insmed is headquartered in Bridgewater, New Jersey.

How long will Insmed's webcasts be available after the event?

Webcasts will remain archived for 30 days post-event.

Last updated: Jan 2, 2025